Active Anti-HIV Guanosine/Thymidine Oligonucleotides

We will develop a new class of oligonucleotides, which fold themselves into ordered structures andmainly of deoxyguanosine and deoxythymidine (GTOs), as therapeutic antiviral agents active against HGTOs as antiviral agents represents the results of a productive investigation into the mechanism bymediate antiviral activity. Experiments described in the following preliminary results section demonguanosine/thymidine compound I100-15, with a phosphodiester (PD) backbone, is able to suppress HIV-1after removal of the drug from the viral infected cell culture is folded into an intramolecular strutranscription; may inhibit critical portions of HIV-1 replication and is not working by blocking virinteraction with the viral v3 loop. The experiments proposed in this Phase I grant application are svalidate the anti-human immunodeficiency virus type 1 (HIV-1) efficacy of 1100-15 by determining thestructure of this molecule and establishing the anti-HIV-1 mechanism of action. A secondary goal ofobtained structural information to rationally design modifications which will increase the anti-HIV-